Results 21 to 30 of about 64,054 (239)

Severe Immune‐Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single‐Center Study [PDF]

open access: yesEuropean Journal of Neurology
ABSTRACT Background Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of various malignancies. The resulting activation of the immune system may lead to neurological immune‐related adverse events (n‐irAEs).
Anna Grisold   +10 more
openaire   +3 more sources

Demyelination of the central nervous system and peripheral neuropathy associated with sintilimab treatment for lung adenocarcinoma: a case report [PDF]

open access: yesJournal of Medical Case Reports
Background Immune checkpoint inhibitor (ICI) therapy unleashes the body’s natural immune system to fight cancer. Neurological immune-related adverse events (NirAEs) are rare but can be severe.
Haibo Deng   +4 more
doaj   +2 more sources

Consensus disease definitions for the spectrum of neurologic immune related adverse events. [PDF]

open access: yesJournal of Clinical Oncology, 2021
2647 Background: Expanding FDA-approved indications for immune checkpoint inhibitors in patients with cancer has resulted in both therapeutic success and immune related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1-12% and a high fatality rate relative to other irAEs.
Amanda C Guidon   +5 more
  +8 more sources

Neurological Immune-Related Adverse Events After COVID-19 Vaccination: A Systematic Review [PDF]

open access: yesNeurology, 2022
AbstractThe coronavirus disease 2019 (COVID‐19) pandemic has affected millions of individuals worldwide. The global scientific effort to design an effective vaccine against this virus has led to the development of several vaccine candidates. The expedited rollout of these vaccines has created some public distrust regarding the safety of these new ...
Ameena Shafiq   +12 more
openaire   +2 more sources

Camrelizumab-Induced Isolate Abducens Neuritis: A Rare Ophthalmic Immune-Related Adverse Events

open access: yesBrain Sciences, 2022
Background: Anti-tumor immunotherapy with immune checkpoint inhibitors induces several immune-related adverse events. Camrelizumab-related isolate abducens neuritis is rare.
Yanli Hou   +3 more
doaj   +1 more source

Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab

open access: yesFrontiers in Neurology, 2021
A 63-year-old male with metastatic non-small cell lung cancer developed longitudinal extensive transverse myelitis (LETM) following two cycles of Pembrolizumab, an immune checkpoint inhibitor (ICI) targeting the programmed cell death receptor 1 (PD-1 ...
Salma Charabi   +4 more
doaj   +1 more source

A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder

open access: yesCase Reports in Oncology, 2021
Immunotherapy has become the standard of care for various cancer types. The widespread use of immune checkpoints inhibitors confronts us with a whole range of novel immune-related adverse events.
Xiaoxiao Wang   +5 more
doaj   +1 more source

Atezolizumab-induced subacute cerebellar ataxia in a patient with extensive-stage small cell lung cancer

open access: yesTherapeutic Advances in Medical Oncology, 2023
Recently, immune checkpoint inhibitors (ICIs) have become the standard treatment option for patients with lung cancer, including small cell lung cancer (SCLC).
Chun-Chia Chen   +3 more
doaj   +1 more source

Neurotoxicity in the Era of Immune Checkpoint Inhibitors: A Case-Based Approach

open access: yesJournal of Oncological Sciences
Immune checkpoint inhibitors (ICIs) have transformed the field of cancer immunotherapy and led to substantial improvements in patient outcomes across various malignancies. Neurological toxicities arising from ICI treatment represent a heterogeneous group
Özkan ALAN   +12 more
doaj   +1 more source

High-dose interleukin-2 therapy related adverse events and implications on imaging

open access: yesDiagnostic and Interventional Radiology, 2021
High-dose interleukin-2 (HDIL-2) therapy was initially approved by the U.S. Food and Drug Administration for metastatic renal cell carcinoma (mRCC) and metastatic melanoma.
Neal R. Shah   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy